Page 5 - Accelerated Approval Program News Today

68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with a remarkable saf...

FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)

BASEL (dpa-AFX) - Novartis (NVS) said that the U.S. Food and Drug Administration granted accelerated approval to Vijoice or alpelisib for the treatment of adult and pediatric patients 2 years of

Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1 PROS is a...

Investegate announcements from NOVARTIS AG CHF0.50(REGD), FDA approves Novartis Vijoice® (alpelisib) as first and only treatment for select patients with PIK3CA-Related Overgrowth Spectrum (PROS)

Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1 PROS is a spectrum of rare conditions and is characterized by

Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1 PROS is a spectrum...

BASEL (dpa-AFX) - Swiss drug major Novartis (NVS) announced Monday that the US Food and Drug Administration approved Scemblix (asciminib) for the treatment of chronic myeloid leukemia or CML in

  Scemblix provides much-needed and long-awaited new option for patients with chronic myeloid leukemia (CML) who suffer with intolerance or inadequate...

Investegate announcements from NOVARTIS AG CHF0.50(REGD), FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia